Professor Marco Gerlinger specialises in the treatment of patients with bowel, stomach and oesophageal cancers at HCA LOC (Leaders in Oncological Care) and The Harley Street Clinic. He is also a Consultant Medical Oncologist, Chair of Gastrointestinal Cancer Medicine and the Director of GI Cancer Research at St Bartholomew’s Hospital and Queen Mary University of London.

Prof Gerlinger studied Medicine at the University of Munich, Harvard Medical School and Imperial College and obtained his research MD from the Institute of Immunology in Munich. He trained in General Medicine and Medical Oncology in Zurich and London and undertook post-doctoral research training in Zurich and at the CRUK London Research Institute (now The Francis Crick Institute).

In 2013, Prof Gerlinger joined the Royal Marsden Hospital as a consultant in GI cancer and the Institute of Cancer Research as a research team leader. He was subsequently appointed at St Bartholomew’s Hospital and Queen Mary University London in 2022. With his team, he leads clinical trials and develops precision medicine biomarkers and new immunotherapies for early-stage and advanced or metastatic bowel, stomach and oesophageal cancers.

Prof Gerlinger is a faculty member of the American Society of Clinical Oncology and the European Society of Medical Oncology Annual Meetings 2022 and of scientific committees of the American Association of Cancer Research.